p53R2 Inhibits the Proliferation of Human Cancer Cells in Association with Cell-Cycle Arrest
- 1 February 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 10 (2) , 269-278
- https://doi.org/10.1158/1535-7163.mct-10-0728
Abstract
Deregulation of the expression of p53R2, a p53-inducible homologue of the R2 subunit of ribonucleotide reductase, has been found in various human cancer tissues; however, the roles p53R2 plays in cancer progression and malignancy remain controversial. In the present study, we examined changes in gene expression profiles associated with p53R2 in cancer cells, using the analysis of cDNA microarray. Gene set enrichment analysis identified that the gene set regulating cell-cycle progression was significantly enriched in p53R2-silencing human oropharyngeal carcinoma KB cells. Attenuation of p53R2 expression significantly reduced p21 expression and moderately increased cyclin D1 expression in both wild-type p53 cancer cells (KB and MCF-7) and mutant p53 cancer cells (PC3 and MDA-MB-231). Conversely, overexpression of p53R2-GFP resulted in an increase in the expression of p21 and decrease in the expression of cyclin D1, which correlated with reduced cell population in S-phase in vitro and suppressed growth in vivo. Furthermore, the MAP/ERK kinase inhibitor PD98059 partially abolished modulation of p21 and cyclin D1 expression by p53R2. Moreover, under the conditions of nonstress and adriamycin-induced genotoxic stress, attenuation of p53R2 in KB cells significantly increased phosphorylated H2AX, which indicates that attenuation of p53R2 may enhance DNA damage induced by adriamycin. Overall, our study shows that p53R2 may suppress cancer cell proliferation partially by upregulation of p21 and downregulation of cyclin D1; p53R2 plays critical roles not only in DNA damage repair but also in proliferation of cancer cells. Mol Cancer Ther; 10(2); 269–78. ©2011 AACR.Keywords
All Related Versions
This publication has 37 references indexed in Scilit:
- Ribonucleotide reductase small subunit p53R2 suppresses MEK–ERK activity by binding to ERK kinase 2Oncogene, 2009
- Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesisMolecular Cancer, 2009
- Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasisBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2009
- ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damageProceedings of the National Academy of Sciences, 2008
- γH2AX and cancerNature Reviews Cancer, 2008
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Expression of p53R2 Is Related to Prognosis in Patients with Esophageal Squamous Cell CarcinomaClinical Cancer Research, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetesNature Genetics, 2003
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993